VOLITIONRX LTD
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
VNRX$0.18-7.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Revenues | $ | $ | $ | $ |
| Services | 161,778 | 116,090 | 277,254 | 155,866 |
| Product | 244,910 | 279,707 | 375,819 | 411,466 |
| Total Revenues | 406,688 | 395,797 | 653,073 | 567,332 |
| Operating Expenses | ||||
| Research and development | 2,720,207 | 3,715,797 | 5,327,321 | 8,345,324 |
| General and administrative | 2,940,754 | 2,284,041 | 5,184,116 | 4,537,784 |
| Sales and marketing | 1,043,534 | 1,386,378 | 1,960,833 | 3,059,147 |
| Total Operating Expenses | 6,704,495 | 7,386,216 | 12,472,270 | 15,942,255 |
| Operating Loss | (6,297,807) | (6,990,419) | (11,819,197) | (15,374,923) |
| Other Income (Expenses) | ||||
| Grant income | 75,991 | - | 197,227 | - |
| Gain (Loss) on disposal of fixed assets | 330 | (33,498) | 330 | (33,498) |
| Interest income | 160 | 450 | 318 | 9,104 |
| Interest expense | (123,356) | (81,182) | (220,025) | (158,415) |
| Amortization of debt discount | (325,305) | - | (325,305) | - |
| Gain on change in fair value of derivative liability | 418,681 | - | 418,681 | - |
| Gain (loss) on change in fair value of warrant liability | (62,764) | 44,474 | (42,726) | 25,552 |
| Total Other Income (Expenses) | (16,263) | (69,756) | 28,500 | (157,257) |
| Net Loss | (6,314,070) | (7,060,175) | (11,790,697) | (15,532,180) |
| Net Loss Attributable to Non-Controlling Interest | 29,992 | 74,629 | 82,860 | 179,246 |
| Net Loss Attributable to VolitionRx Limited Stockholders | (6,284,078) | (6,985,546) | (11,707,837) | (15,352,934) |
| Other Comprehensive Income (Loss) | ||||
| Foreign currency translation adjustments | (575,996) | 23,024 | (829,925) | 38,312 |
| Net Comprehensive Loss | (6,890,066) | (7,037,151) | (12,620,622) | (15,493,868) |
| Net Loss Per Share – Basic and Diluted Attributable to VolitionRx Limited stockholders | (0.06) | (0.08) | (0.12) | (0.19) |
| Weighted Average Shares Outstanding | ||||
| – Basic and Diluted | 102,654,095 | 82,669,335 | 99,611,974 | 82,312,161 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.